A new study has found that the combination of the immunotherapy drug ipilimumab and the investigational antibody drug nivolumab led to long-lasting tumor shrinkage in more than half of patients with metastatic melanoma. These are the results from a Phase I trial simultaneously published online on Sunday, June 2, in iThe New England Journal of Medicine/i and presented by Memorial Sloan-Kettering Cancer Center/a researchers at the 49th Annual Meeting of the ...Tuesday, 4 June 2013
Combination of Drugs Produces Dramatic Tumor Responses in Advanced Melanoma Patients
A new study has found that the combination of the immunotherapy drug ipilimumab and the investigational antibody drug nivolumab led to long-lasting tumor shrinkage in more than half of patients with metastatic melanoma. These are the results from a Phase I trial simultaneously published online on Sunday, June 2, in iThe New England Journal of Medicine/i and presented by Memorial Sloan-Kettering Cancer Center/a researchers at the 49th Annual Meeting of the ...
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment